Drug intelligence / Profile preview

Kudingxiang Tongqi Suppository

Development stage: Preclinical
Lead developer: SNYK Pharmaceutical
Modality: Small Molecules
Administration: Rectal

Overview

Kudingxiang Tongqi Suppository (TQS) is a pharmaceutical drug being investigated for its safety and efficacy in restoring gastrointestinal function after abdominal surgery. It is administered rectally and is currently undergoing a randomized, double-blinded, placebo-controlled, parallel-grouped, multi-centre clinical study. The drug is developed by Beijing SNYK Pharmaceutical Ltd and Renmin Hospital of Beijing University.

Other names: 苦丁香通气栓

Beyond the preview

Go deeper on Kudingxiang Tongqi Suppository.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kudingxiang Tongqi Suppository.

Explore the full profile